Literature DB >> 23479632

Role of ELOVL4 and very long-chain polyunsaturated fatty acids in mouse models of Stargardt type 3 retinal degeneration.

Peter Barabas1, Aihua Liu, Wei Xing, Ching-Kang Chen, Zongzhong Tong, Carl B Watt, Bryan W Jones, Paul S Bernstein, David Križaj.   

Abstract

Stargardt type 3 (STGD3) disease is a juvenile macular dystrophy caused by mutations in the ELOVL4 (Elongation of very long chain fatty acids 4) gene. Its protein product, ELOVL4, is an elongase required for the biosynthesis of very long-chain polyunsaturated fatty acids (VLC-PUFAs). It is unclear whether photoreceptor degeneration in STGD3 is caused by loss of VLC-PUFAs or by mutated ELOVL4 protein trafficking/aggregation. We therefore generated conditional knockout (cKO) mice with Elovl4 ablated in rods or cones and compared their phenotypes to transgenic (TG) animals that express the human STGD3-causing ELOVL4(STGD3) allele. Gas chromatography-mass spectrometry was used to assess C30-C34 VLC-PUFA and N-retinylidene-N-retinylethanolamine content; electroretinography was used to measure phototransduction and outer retinal function; electron microscopy was used for retinal ultrastructure; and the optomotor tracking response was used to test scotopic and photopic visual performance. Elovl4 transcription and biosynthesis of C30-C34 VLC-PUFAs in rod cKO and TG retinas were reduced up to 98%, whereas the content of docosahexaenoic acid was diminished in TG, but not rod cKO, retinas. Despite the near-total loss of the retinal VLC-PUFA content, rod and cone cKO animals exhibited no electrophysiological or behavioral deficits, whereas the typical rod-cone dystrophic pattern was observed in TG animals. Our data suggest that photoreceptor-specific VLC-PUFA depletion is not sufficient to induce the STGD3 phenotype, because depletion alone had little effect on photoreceptor survival, phototransduction, synaptic transmission, and visual behavior.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23479632      PMCID: PMC3612655          DOI: 10.1073/pnas.1214707110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

Review 1.  Chaperones come of age.

Authors:  Csaba Soti; Péter Csermely
Journal:  Cell Stress Chaperones       Date:  2002-04       Impact factor: 3.667

2.  Expression of wild type and mutant ELOVL4 in cell culture: subcellular localization and cell viability.

Authors:  Goutam Karan; Zhenglin Yang; Kang Zhang
Journal:  Mol Vis       Date:  2004-03-31       Impact factor: 2.367

3.  Loss of functional ELOVL4 depletes very long-chain fatty acids (> or =C28) and the unique omega-O-acylceramides in skin leading to neonatal death.

Authors:  Vidyullatha Vasireddy; Yoshikazu Uchida; Norman Salem; Soo Yeon Kim; Md Nawajesh Ali Mandal; Geereddy Bhanuprakash Reddy; Ravi Bodepudi; Nathan L Alderson; Johnie C Brown; Hiroko Hama; Andrzej Dlugosz; Peter M Elias; Walter M Holleran; Radha Ayyagari
Journal:  Hum Mol Genet       Date:  2007-01-05       Impact factor: 6.150

4.  Kinetics of the photocurrent of retinal rods.

Authors:  R D Penn; W A Hagins
Journal:  Biophys J       Date:  1972-08       Impact factor: 4.033

5.  Diverse macular dystrophy phenotype caused by a novel complex mutation in the ELOVL4 gene.

Authors:  P S Bernstein; J Tammur; N Singh; A Hutchinson; M Dixon; C M Pappas; N A Zabriskie; K Zhang; K Petrukhin; M Leppert; R Allikmets
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-12       Impact factor: 4.799

6.  Rods and cones in the mouse retina. I. Structural analysis using light and electron microscopy.

Authors:  L D Carter-Dawson; M M LaVail
Journal:  J Comp Neurol       Date:  1979-11-15       Impact factor: 3.215

7.  A 5-bp deletion in ELOVL4 is associated with two related forms of autosomal dominant macular dystrophy.

Authors:  K Zhang; M Kniazeva; M Han; W Li; Z Yu; Z Yang; Y Li; M L Metzker; R Allikmets; D J Zack; L E Kakuk; P S Lagali; P W Wong; I M MacDonald; P A Sieving; D J Figueroa; C P Austin; R J Gould; R Ayyagari; K Petrukhin
Journal:  Nat Genet       Date:  2001-01       Impact factor: 38.330

8.  Essential role of ELOVL4 protein in very long chain fatty acid synthesis and retinal function.

Authors:  Richard Harkewicz; Hongjun Du; Zongzhong Tong; Hisham Alkuraya; Matthew Bedell; Woong Sun; Xiaolei Wang; Yuan-Hao Hsu; Julian Esteve-Rudd; Guy Hughes; Zhiguang Su; Ming Zhang; Vanda S Lopes; Robert S Molday; David S Williams; Edward A Dennis; Kang Zhang
Journal:  J Biol Chem       Date:  2011-12-24       Impact factor: 5.157

9.  Differential effect of the rd mutation on rods and cones in the mouse retina.

Authors:  L D Carter-Dawson; M M LaVail; R L Sidman
Journal:  Invest Ophthalmol Vis Sci       Date:  1978-06       Impact factor: 4.799

10.  Atrophic macular degeneration mutations in ELOVL4 result in the intracellular misrouting of the protein.

Authors:  Rajesh Ambasudhan; XiaoFei Wang; Monica M Jablonski; Debra A Thompson; Pamela S Lagali; Paul W Wong; Paul A Sieving; Radha Ayyagari
Journal:  Genomics       Date:  2004-04       Impact factor: 5.736

View more
  22 in total

1.  Examination of VLC-PUFA-deficient photoreceptor terminals.

Authors:  Lea D Bennett; Blake R Hopiavuori; Richard S Brush; Michael Chan; Matthew J Van Hook; Wallace B Thoreson; Robert E Anderson
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-24       Impact factor: 4.799

2.  n-3 PUFA Supplementation Alters Retinal Very-Long-Chain-PUFA Levels and Ratios in Diabetic Animal Models.

Authors:  Aruna Gorusupudi; Fu-Yen Chang; Kelly Nelson; Gregory S Hageman; Paul S Bernstein
Journal:  Mol Nutr Food Res       Date:  2019-06-28       Impact factor: 5.914

3.  Retinal bioavailability and functional effects of a synthetic very-long-chain polyunsaturated fatty acid in mice.

Authors:  Aruna Gorusupudi; Rameshu Rallabandi; Binxing Li; Ranganathan Arunkumar; J David Blount; Gregory T Rognon; Fu-Yen Chang; Alexander Wade; Steven Lucas; John C Conboy; Jon D Rainier; Paul S Bernstein
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-09       Impact factor: 11.205

Review 4.  Psychophysical testing in rodent models of glaucomatous optic neuropathy.

Authors:  Stephanie L Grillo; Peter Koulen
Journal:  Exp Eye Res       Date:  2015-07-02       Impact factor: 3.467

5.  Mouse Models of Stargardt 3 Dominant Macular Degeneration.

Authors:  Peter Barabas; Aruna Gorusupudi; Paul S Bernstein; David Krizaj
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

6.  STAT3 promotes survival of mutant photoreceptors in inherited photoreceptor degeneration models.

Authors:  Ke Jiang; Katherine L Wright; Ping Zhu; Michael J Szego; Alexa N Bramall; William W Hauswirth; Qiuhong Li; Sean E Egan; Roderick R McInnes
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

7.  Elovl4 and Fa2h expression during rat spermatogenesis: a link to the very-long-chain PUFAs typical of germ cell sphingolipids.

Authors:  Florencia X Santiago Valtierra; Daniel A Peñalva; Jessica M Luquez; Natalia E Furland; Claudia Vásquez; Juan G Reyes; Marta I Aveldaño; Gerardo M Oresti
Journal:  J Lipid Res       Date:  2018-05-03       Impact factor: 5.922

8.  Effect of reduced retinal VLC-PUFA on rod and cone photoreceptors.

Authors:  Lea D Bennett; Richard S Brush; Michael Chan; Todd A Lydic; Kristen Reese; Gavin E Reid; Julia V Busik; Michael H Elliott; Robert E Anderson
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-10       Impact factor: 4.799

9.  Associations of human retinal very long-chain polyunsaturated fatty acids with dietary lipid biomarkers.

Authors:  Aruna Gorusupudi; Aihua Liu; Gregory S Hageman; Paul S Bernstein
Journal:  J Lipid Res       Date:  2016-01-13       Impact factor: 5.922

10.  Mutant ELOVL4 that causes autosomal dominant stargardt-3 macular dystrophy is misrouted to rod outer segment disks.

Authors:  Martin-Paul Agbaga; Beatrice M Tam; Jenny S Wong; Lee Ling Yang; Robert E Anderson; Orson L Moritz
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-15       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.